ELI LILLY LAUNCHES NEW HEART MEDICINE
By Adnews Staff
Montreal-based Eli Lilly Canada on Monday launched ReoPro, a new heart medicine that has been proven to significantly reduce the incidence of death and major complications after angioplasty procedures. ReoPro, also known as abciximab, is used in combination with balloon angioplasty, a surgical procedure designed to open clogged arteries in patients at risk of heart attacks and death. Clinical trial data showed that ReoPro reduced the incidence of heart attack and death following angioplasty by up to 59%. The drug, launched in the U.S. eight months ago, will be advertised in Canadian medical journals from late September to the end of the year. The ads were created by Remtulla + Associates of Toronto, which also bought the media.